Test Price
2,800 AED✅ Home Collection Available
WHRN Gene Deafness, Autosomal Recessive Type 31 Genetic Test | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — Available daily from 8 AM to 11 PM by DHA-Licensed phlebotomist.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for Result Interpretation and Next Steps from a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The WHRN Gene Deafness, Autosomal Recessive Type 31 Genetic Test uses Next-Generation Sequencing (NGS) to detect pathogenic variants in the WHRN gene, the molecular cause of DFNB31 non-syndromic sensorineural hearing loss and Usher syndrome type 2D. This definitive genomic analysis enables early audiological intervention, cochlear implant candidacy assessment, and informed familial genetic counseling.
| Feature | Our WHRN NGS Test | Standard Single-Gene Sequencing |
|---|---|---|
| Methodology | NGS – Full gene coverage, CNV detection | Sanger sequencing – targeted exons only |
| Analytical Sensitivity | >99.9% for SNVs and indels | ~99% (limited to analysed regions) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Utility | Comprehensive – DFNB31 & Usher type 2D | Limited – may miss deep intronic/CNV |
Physician Insight & Safety Protocols
"Hearing loss diagnosed through genomic sequencing provides families with a clear molecular roadmap for early intervention and tailored support. The identification of a pathogenic WHRN variant allows for precise prognostic counseling and informed decisions regarding cochlear implantation and educational planning. Genetic results must always be interpreted alongside comprehensive audiological assessments to ensure the best clinical outcomes."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory Notice
Ongoing Care Advisory: Do not discontinue prescribed medication, hearing aids, or other audiological interventions without consulting your treating physician. Genetic test results should complement, not replace, regular clinical follow-up with an ENT specialist or audiologist.
Safety Exclusion & Emergency Red Flags
Patient Exclusion Criteria
- This test is contraindicated for individuals with active systemic infection or those unable to provide informed consent. A mandatory pre-test genetic counseling session with a qualified medical geneticist is required to confirm clinical appropriateness and obtain written consent.
Emergency Red Flags
- If the patient experiences sudden onset of profound hearing loss, severe vertigo, persistent tinnitus, or any new neurological deficits such as facial weakness or balance disturbance, seek immediate emergency medical attention. Do not wait for genetic test results or scheduled appointments.
Patient FAQ & Clinical Guidance
1. What is the WHRN gene test and who should consider it?
The WHRN gene test screens for pathogenic variants causing autosomal recessive deafness type 31 (DFNB31) and Usher syndrome type 2D. It is recommended for individuals with congenital or early-onset bilateral sensorineural hearing loss, particularly those with a family history suggestive of autosomal recessive inheritance. Early molecular diagnosis enables prompt audiological rehabilitation and genetic counseling for at-risk family members.
2. How is the sample collected and what type of specimen is required?
A standard peripheral whole blood sample is collected via routine venipuncture, or a non-invasive FTA card finger-prick sample may be used for pediatric patients. The draw is performed by a DHA-licensed phlebotomist through our VIP Mobile Phlebotomy service, available daily from 8 AM to 11 PM. Samples are transported under ISO-certified cold-chain conditions to our laboratory.
3. How long do results take and what post-test support is provided?
Results are delivered within 3 to 4 weeks from sample receipt. A comprehensive clinical report is issued, and all patients receive a telephonic post-test consultation with our Consultant Medical Geneticist to discuss findings, prognostic implications, and recommended next steps including referrals, insurance coordination, and family cascade testing where indicated.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Security Compliance: DNA Labs UAE fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic and personal data are encrypted, access-controlled, and processed exclusively within secure UAE-based infrastructure. Clinical testing safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that every step from sample collection to result disclosure follows the highest standards of medical accountability.
Clinical & Logistical Metadata
| Test Name | WHRN Gene Deafness, Autosomal Recessive Type 31 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or FTA Card Finger-Prick (VIP Mobile Phlebotomy Eligible) |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV Detection |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 55233-1 |
| DHA Facility License & Address | DHA Facility License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians